All the news Showing 10 of 56 articles from: Genotype 1bGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Faldaprevir safe and effective in HCV treatment-experienced patients Michael Carter / 13 December 2013 Triple therapy including the investigational hepatitis C virus (HCV) protease inhibitor faldaprevir is a safe and effective treatment for people who did not respond to a previous course of HCV treatment, results of ... Daclatasvir + asunaprevir cures 85% of genotype 1b hepatitis C patients in Japanese study Liz Highleyman / 27 November 2013 An interferon- and ribavirin-free oral regimen of daclatasvir plus asunaprevir taken for 24 weeks led to sustained virological response (SVR12) in 85% of Japanese patients with hepatitis C virus subtype 1b, according to ... AbbVie reports 96% cure rate for interferon-free hepatitis C regimen in phase 3 study Keith Alcorn / 18 November 2013 An interferon-free combination of three drugs plus ribavirin achieved a sustained virologic response (SVR12) in 96% of previously untreated patients with genotype 1 hepatitis C infection, AbbVie reported in a press release on ... Faldaprevir plus pegylated interferon/ribavirin leads to early sustained response in people with HIV and HCV co-infection Liz Highleyman / 14 November 2013 The hepatitis C protease inhibitor faldaprevir plus pegylated interferon and ribavirin improved 4-week sustained response rates for HIV-positive people with genotype 1 hepatitis C co-infection in the STARTVerso4 trial, according to a ... Faldaprevir effective across patient sub-groups with several baseline characteristics associated with treatment outcomes Michael Carter / 14 November 2013 The experimental hepatitis C virus (HCV) protease inhibitor faldaprevir is efficacious across a range of subgroups of patients with genotype 1 infection, according to research presented to the recent Liver Meeting 2013, the ... Fixed-dose sofosbuvir/ledipasvir with or without ribavirin cures most genotype 1 hepatitis C patients, LONESTAR study shows Liz Highleyman / 13 November 2013 At least 95% of newly treated people with genotype 1 hepatitis C and prior non-responders achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to ... Sofosbuvir + ribavirin produces sustained response in 76% of genotype 1 HIV/HCV co-infected people Liz Highleyman / 08 November 2013 An interferon-free regimen of sofosbuvir plus ribavirin taken for 24 weeks cured hepatitis C infection in three quarters of previously untreated HIV-positive people co-infected with hepatitis C virus (HCV) genotype 1, while ... BMS interferon-free combination cures over 90% of genotype 1 hepatitis C in 12 weeks Keith Alcorn / 06 November 2013 A combination of three direct-acting antivirals developed by Bristol-Myers Squibb cured chronic hepatitis C infection in over 90% of previously untreated patients in a mid-stage study, Gregory Everson of the University of Colorado ... In ELECTRON trial, 100% of hard-to-treat patients cured with sofosbuvir/ledipasvir plus ribavirin or GS-9669 Liz Highleyman / 05 November 2013 Interferon-free regimens of sofosbuvir and ledipasvir plus either ribavirin or GS-9669 taken for 12 weeks produced sustained response in 100% of treatment-experienced people with genotype 1 chronic hepatitis C virus (HCV) with advanced ... AbbVie's two-drug, interferon-free combination cures genotype 1b hepatitis C infection in 95% Keith Alcorn / 05 November 2013 A two-drug combination of direct-acting antivirals developed by AbbVie achieved sustained virologic response in 95% of previously untreated patients with genotype 1b hepatitis C infection after 12 weeks of treatment, without the need ... ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive